Management of chronic myeloid leukaemia in clinical practice in France: Results of the French subset of patients from the UNIC studyCML management in France

摘要

Objective: To assess real-life treatment practices with imatinib for chronic-phase chronic myeloid leukaemia (CP-CML) in France. Research design and methods: In the observational Unmet Needs in CML (UNIC) study of CML management in Europe, case report forms were completed retrospectively for eligible patients (≥18 years of age, currently treated for CML) during enrolment (September 2006March 2007). Results from the subset of patients from France are presented. Main outcome measures: Primary objectives were to estimate from the collected data the proportions of patients ever treated with imatinib and those experiencing imatinib resistance and/or intolerance as determined by physicians diagnoses of resistance/intolerance leading to a change in imatinib use. Collected data were analysed descriptively. Secondary descriptive measures included imatinib dose modifications and methods for treatment response monitoring. Results: Of the 654 French CP-CML patients, 95.9 had received imatinib. Of these, 15 were judged by physicians as imatinib-resistant and 31 as imatinib-intolerant (not mutually exclusive) during treatment, 44 required dose modification and 23 discontinued imatinib. In the 12 months preceding the last observation, 65 had a cytogenetic features analysis and 93 had a polymerase chain reaction (PCR) assessment of molecular response. Importantly, and contrasting with European recommendations, 46 of imatinib-resistant patients had never been assessed for BCR-ABL mutations. Limitations: The observational study design limits data collection and interpretation. The findings are specific to the French healthcare system and may not apply to other countries. Conclusion: This observational study of CP-CML management in France confirmed that most patients are treated with imatinib, a treatment widely recognised as efficacious. The study highlights opportunities for optimising CML management, as a proportion of patients may require alternative treatment strategies due to imatinib resistance/intolerance. Response monitoring rates differ from recommendations, representing another opportunity for improving care for CP-CML patients through early identification of patients failing current therapy.